Full Text
EE340 Do We Need to Measure Social Impact of Innovative Drugs?

Abstract

Authors

Malgorzata Budasz Swiderska Michal Seweryn JOANNA AUGUSTYNSKA Karolina Skóra

Back to Volume 28, Supplemental Issue 12S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×